

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps

[ID6379]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

A stakeholder noted that access to treatment with tezepelumab may be difficult because:

- | |
|---|
| <ul style="list-style-type: none">• eligibility criteria can limit access for some patients, particularly if they do not meet specific clinical thresholds• geographical location may present barriers, especially where treatments are delivered through specialist centres, potentially disadvantaging individuals living in areas with limited access to such services. |
|---|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The committee can only appraise the technology within its marketing authorisation and based on the evidence available. The committee will consider whether its recommendation has any impact on potential equality issues or health inequalities, The committee should be mindful of the extent to which their recommendations could disadvantage a particular group.

Issues related to access to services, such as geographical location, cannot be addressed in a technology appraisal.

Health Technology Evaluation: Scoping
Equality impact assessment for the Health Technology Evaluation of tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
	No

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
	N/a

Approved by Associate Director: Emily Crowe

Date: 28/11/2025